NPCE News & Analysis
2 articles
Market Mood
NeuroPace (NPCE) Receives FDA Approval for ECoG Assistant™
NeuroPace, Inc. (NPCE) announced on May 29 that it received FDA approval for its ECoG Assistant, an AI-driven feature designed to enhance epilepsy care using long-term intracranial EEG data. The tool is built on 124,450 epileptologist-labeled records, providing physicians with insights through integrated reports and charts. This approval represents a significant step towards practical tools for clinicians according to CEO Joel Becker. The company is also targeting FDA approval for its next-generation patient data platform in the second quarter of 2026.
Read More
NeuroPace (NPCE) Stock Price Target Raised to $20 by H.C. Wainwright
H.C. Wainwright has increased its price target for NeuroPace (NPCE) to $20. This revision is based on the company's guidance, which suggests positive performance expectations in the near term. The bullish forecast may attract investor interest, potentially impacting NPCE's market performance. Analysts often adjust targets based on company guidance, making this development significant for current and prospective shareholders.
Read More